Gaspar Aspas Requena

Gaspar Aspas Requena

Auto-generated profile, based on publicly available information

Gaspar Aspas Requena

15Hématologie Clinique, CHU de Montpellier, Montpellier, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
CLCurtis Lachowiez
Curtis Lachowiez
MHMael Heiblig
Mael Heiblig
GRGaspar Aspas Requena
Gaspar Aspas Requena
ETEmmanuelle Tavernier-Tardy
Emmanuelle Tavernier-Tardy
FDFangyan Dai
Fangyan Dai
DPDaniel A. Pollyea
Daniel A. Pollyea
Resistance to venetoclax (VEN)-based therapy in acute myeloid leukemia (AML) includes genetic (i.e., mutations in N/KRAS, FLT3-ITD, TP53) and phenotypic (i.e., monocytic differentiation) features. Whether monocytic differentiation contributes to clinical VEN resistance secondary to a genetic bias remains unknown. This multimodal, multicenter, international analysis, inclusive of 678 patients, comprehensively characterized the prognostic role of monocytic differentiation in patients with AML treated with hypomethylating agents combined with VEN. AML genetics and monocytic differentiation (HR = 1.89; 95% confidence interval, 1.35–2.66; P < 0.001) in NPM1 wild-type cases correlated with an increased risk of death, clustering of centralized quantitative multiparameter flow cytometry data, evaluation of RNA sequencing-derived AML maturation stage, and single-cell proteogenomics linked driver mutations with AML phenotype and antiapoptotic gene expression. This comprehensive analysis of AML genetics, phenotype, and antiapoptotic protein expression highlights the complementary role these factors impart following VEN-based therapy. Significance: AML with monocytic differentiation often occurs in the context of co-occurring mutations within signaling pathways. In certain AML subgroups (such as NPM1 wild-type and signaling pathway gene–mutated), a monocytic phenotype is associated with decreased overall survival following VEN-based therapy. See related commentary by Renders, p. 403

1 September 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CLCurtis Lachowiez
Curtis Lachowiez
JZJoshua F. Zeidner
Joshua F. Zeidner
JOJad Othman
Jad Othman
AKAndy Kaempf
Andy Kaempf
SYSeongseok Yun
Seongseok Yun
RWRina Li Welkie
Rina Li Welkie
PURPOSE: As risk stratification for patients with AML treated with lower-intensity venetoclax-based therapy remains suboptimal, we developed and validated a prognostic model integrating clinical, cytogenetic, and molecular features. METHODS: We assembled a multinational data set comprising 2,092 adults with newly diagnosed AML treated with hypomethylating agents plus venetoclax (HMA + VEN). One thousand nine hundred eighteen patients with complete data were randomly divided into training (70%) and internal validation (30%) cohorts. Two independent external validation cohorts were assembled (n = 500 and n = 222). Modeling overall survival (OS), Elastic Net regression was applied in 1,000 bootstrap samples from the training cohort to select variables for a Ridge regression, which generated a continuous Prognostic Risk Integration for Survival Modeling (PRISM) score and risk categories based on tertiles (PRISM-3: low, moderate, high). These PRISM indices were then computed for the validation cohorts and compared with the 4-gene classifier (based on mutations in FLT3 -ITD, N/KRAS , and TP53 ). RESULTS: PRISM integrated 17 clinical and genomic variables and demonstrated a linear association with OS. PRISM-3 stratified survival consistently across all cohorts (median OS: 25.1-28.8 months for low risk, 12.5-14.7 months for moderate risk, and 5.8-6.7 months for high risk; P < .001). Compared with the 4-gene classifier, PRISM-3 reassigned approximately 40% of patients (and >50% of those with favorable risk) and demonstrated significantly better discrimination in validation cohorts (C-index 0.63-0.65 v 0.59-0.61; P < .05). CONCLUSION: PRISM is a validated prognostic model for patients with AML receiving HMA + VEN that improves survival risk stratification beyond current standard tools and supports individualized, risk-adapted clinical decision making. The model, the PRISM-AML Risk Calculator, is publicly available.

17 July 2026 in Leukemia
Verified
Journal Article
Open access
PDF file
MHMael Heiblig
Mael Heiblig
ZGZofia Gross
Zofia Gross
ABAmine Belhabri
Amine Belhabri
UTUrbain Tauveron-Jalenques
Urbain Tauveron-Jalenques
ETEmmanuelle Tavernier
Emmanuelle Tavernier
FGFrench AURAML group
French AURAML group
Measurable residual disease (MRD) is a key prognostic marker in acute myeloid leukemia (AML), but its significance in patients treated with azacitidine and venetoclax (AZA/VEN) outside clinical trials remains unclear. We retrospectively analyzed 220 newly diagnosed AML patients from the French VENAURA registry who achieved composite complete remission and underwent MRD evaluation by multiparametric flow cytometry (MFC, LAIP/LSC) and/or NPM1 RT-qPCR. Cumulative MRD negativity was achieved in 62–67% of patients. Attaining MRD negativity at any time was strongly associated with superior overall survival (OS: 31.3 months vs 15.7 months (HR = 0.47) for LAIP, not reached vs 10.8 months (HR = 0.38) for NPM1; all p < 0.001) and lower cumulative incidence of relapse. Dual LAIP/LSC negativity (NEG/NEG) conferred the best outcomes compared to NEG/POS (HR = 0.36, p = 0.02), POS/NEG (HR = 0.24, p < 0.001) and POS/POS (HR = 0.26, p = 0.26) status. Importantly, MRD response mitigated the adverse prognostic impact of ELN 2024 intermediate/poor risk, with MRD-negative patients achieving outcomes comparable to favorable-risk cases. MRD kinetics (early vs late responders) did not affect survival, while G-CSF use improved MRD conversion and OS. In real-world AZA/VEN–treated AML, achieving deep MRD negativity, by MFC or NPM1 RT-qPCR, emerges as the dominant prognostic determinant, overriding baseline risk and supporting its integration into response-adapted strategies.

24 March 2026 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
UTUrbain Tauveron-Jalenques
Urbain Tauveron-Jalenques
GRGaspar Aspas Requena
Gaspar Aspas Requena
ZGZofia Gross
Zofia Gross
ETEmmanuelle Tavernier
Emmanuelle Tavernier
PCPedro Chorão
Pedro Chorão
MHMael Heiblig
Mael Heiblig
Fit relapsed/refractory (R/R) acute myeloid leukemia (AML) patients usually undergo intensive chemotherapy (IC)-based salvage to bridge them to allogeneic hematopoietic stem cell transplantation (HSCT), but their prognosis remains poor. Azacitidine and venetoclax (AZA/VEN) are increasingly used as salvage therapy in R/R AML with encouraging results, although data remain limited. In this study, we evaluated the post-HSCT outcomes of 75 R/R AML patients from the VENAURA registry who underwent HSCT after AZA/VEN salvage. After a median follow-up of 16.9 months, the estimated 2-year overall survival (OS) was 61.4% (95% confidence interval [CI]: 49.5–68.1%). The 2-year cumulative incidence of relapse (CIR) was 35.1% (95% CI: 20–50.2%). The estimated 2-year non-relapse mortality (NRM) rate was 10.6% (95% CI: 9.8–23.3%). Cytological response at the end of cycle 1 was independently associated with OS and CIR in multivariate analysis. Comparison with 75 pair-matched patients receiving IC-based salvage prior to HSCT revealed similar OS in both groups. CIR was not significantly higher in AZA/VEN-treated compared to IC-treated patients; however, there was a trend toward a lower 2-year NRM rate in the AZA/VEN group. Our data suggest that AZA/VEN represents a feasible bridge-to-transplant option with a favorable toxicity profile.

22 April 2026 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
GRGaspar Aspas Requena
Gaspar Aspas Requena
RRRebeca Rodríguez-Veiga
Rebeca Rodríguez-Veiga
CGCristina Gil
Cristina Gil
CBCarmen Botella
Carmen Botella
EAEliana Aguiar
Eliana Aguiar
PMPau Montesinos
Pau Montesinos
In a large multicenter real‐world cohort, we aimed to evaluate outcomes of FLAG‐Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary refractory disease (36.9%) and first relapse episode (63.1%), with a median age of 52 years. Complete remission composite (CRc) was achieved 56.8%, including complete remission (CR) in 51.0%, CR with incomplete recovery in 4.0%, and morphological‐free‐state in 1.8%, enabling 35.2% of patients and 62% of responders to proceed to allogeneic transplantation without morphological disease. With median follow‐up of 50.9 months, median overall survival (OS) was 10.2 months, with 5‐year OS rate of 21.6%. Prior allogeneic transplantation (HR 0.54; p < 0.001) and relapse‐free interval ≥ 1 year (HR 0.75; p = 0.024) independently predicted improved OS, whereas modified high‐risk cytogenetics including t (8; 21) (HR 3.58; p < 0.001), FLT3 ‐ITD mutation at primary diagnosis (HR 1.61; p < 0.001), and age ≥ 60 (HR 1.43; p < 0.001) conferred inferior OS. Validation of the SALFLAGE score demonstrated moderate discrimination (C‐index 0.67), with 5‐year survival of 38.4%, 27.2%, and 12.7% across risk categories ( p < 0.001). Outcomes improved over periods (1998–2005 vs. 2006–2016 vs. 2017–2024): 30‐day mortality was 6.9% vs. 9.3% vs. 5.0%, respectively ( p = 0.030), and median OS was 7.8 versus 9.4 versus 11.1 months, respectively ( p = 0.16). We confirm FLAG‐Ida as a reference salvage regimen in fit R/R AML and validate the SALFLAGE score in this setting.

11 February 2026 in American Journal of Hematology
Verified
Journal Article
Open access
GRGaspar Aspas Requena
Gaspar Aspas Requena
PMPau Montesinos
Pau Montesinos
EBEmilie Bérard
Emilie Bérard
SBSarah Bertoli
Sarah Bertoli
RRRebeca Rodríguez-Veiga
Rebeca Rodríguez-Veiga
DMDavid Martínez-Cuadrón
David Martínez-Cuadrón
The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3 ‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC ( n = 194) versus IC alone ( n = 371) in 565 patients with FLT3 ‐mutated AML aged ≥ 60 years (median age 67.5 years; 35.6% ≥ 70 years). MIDO+IC was associated with lower day‐60 early death (8.2% vs. 21.4%, p < 0.0001) and higher composite complete remission (CRc) rates (78.9% vs. 63.1%, p < 0.0001). After a median follow‐up of 46.0 months, median overall survival (OS) was 24.2 months for MIDO+IC versus 8.7 months for IC ( p < 0.0001), with 5‐year OS rates of 40.6% vs. 12.9%, respectively. Event‐free survival (EFS; median 13.5 vs. 4.6 months; 5‐year EFS: 36.0% vs. 10.1%) and relapse‐free survival (RFS; median 20.2 vs. 8.0 months; 5‐year RFS: 45.4% vs. 15.7%) were also significantly improved (both p < 0.0001). The 5‐year cumulative incidence of relapse was lower with MIDO+IC (47.8% vs. 67.1%, p < 0.001). In multivariate analyses, midostaurin was an independent favorable prognostic factor for CRc (aOR 1.97 [95% CI: 1.29–2.98]), OS (aHR 0.46 [95% CI: 0.36–0.58]), EFS (aHR 0.49 [95% CI: 0.39–0.60]), and RFS (aHR 0.47 [CI: 0.36–0.62]) (all p ≤ 0.002). These benefits were confirmed by propensity score matching. This large real‐world study demonstrates that combining midostaurin with IC significantly improves remission rates and survival outcomes in elderly patients with FLT3 ‐mutated AML, supporting its consideration in this population.